This is the old version of SRDR. The next, SRDRplus is available! Registration of your SRDRPlus account is free and approval is automatic. Click Here to register an SRDRPlus account.

  • Home
  • Published Projects
  • Registries
Advanced Search

Study Preview



Study Title and Description

Safety and efficacy of PNU-142633, a selective 5-HT1D agonist, in patients with acute migraine.



Key Questions Addressed
2 KQ2a. What is the comparative effectiveness of nonopioid pharmacologic therapy (e.g. acetaminophen, NSAIDs, triptans, ergots alkaloids, combination analgesics, muscle relaxants, anti-nausea medications, and cannabis) versus: 1) other nonopioid pharmacologic treatments, such as those in a different medication class; or 2) nonpharmacologic therapy for outcomes related to pain, function, pain relief satisfaction, and quality of life after followup at the following intervals: < 1 day; 1 day to <1 week; 1 week to <2 weeks; 2 weeks to 4 weeks? KQ2b. How does effectiveness of nonopioid pharmacologic therapy vary depending on: (1) patient demographics (e.g. age, race, ethnicity, gender); (2) patient medical comorbidities; (3) the type of nonopioid medication; (4) dose of medication; (5) duration of treatment? KQ2c. What are the harms of nonopioid pharmacologic therapy versus other nonopioid pharmacologic therapy, or nonpharmacologic therapy with respect to: (1) misuse, (2) overdose; (3) MOH, (4) other harms including gastrointestinal-related harms, cardiovascular-related harms, kidney-related harms, falls, fractures, motor vehicle accidents, endocrinological harms, infections, cognitive harms, and psychological harms (e.g. depression)? KQ2d. How do harms vary depending on: (1) patient demographics (e.g. age, gender); (2) patient medical comorbidities; (3) the type of nonopioid medication; (4) dose of medication; (5) the duration of therapy?
  • Comments Comments (
    0
    ) |
  • Post/View

Primary Publication Information
  • Comments Comments (
    0
    ) |
TitleData
Title Safety and efficacy of PNU-142633, a selective 5-HT1D agonist, in patients with acute migraine.
Author Gomez-Mancilla B., Cutler NR., Leibowitz MT., Spierings EL., Klapper JA., Diamond S., Goldstein J., Smith T., Couch JR., Fleishaker J., Azie N., Blunt DE.
Country Pharmacia & Upjohn Company, Kalamazoo, MI 491001-0199, USA. baltazar.gomez-mancilla@am.pnu.com
Year 2001
Numbers Pubmed ID: 11595000

Secondary Publication Information
There are currently no secondary publications defined for this study.


Extraction Form: Key Question 2
Design Details
Question... Follow Up Answer Follow-up Answer




Results & Comparisons

No Results found.